Abstract
Low density lipoprotein-cholesterol (LDL-C) reduction is the basic approach in the treatment and prevention of cardiovascular disease on the atherosclerosis background. Except of healthy life style, nutriceuticals are possible to recommend for atherogenic lipid profile influencing, e.g.
Armolipid Plus. Results of Armolipid Plus clinical studies are presented; this nutriceutical reduces LDL-C by 15-30 % and glucose level.
Armolipid Plus changed the size and density of LDL particles from small dense to big normodense less atherogenic particles in patients with familial combined hyperlipoproteinemia.is nutriceutical improved endothelial dysfunction and reduced pulse wave velocity. Armolipid Plus is possible to indicate in combination with lipid modifying drugs or itself within healthy life style.